Lansoprazole: A comprehensive review

Pharmacotherapy

Volumn 17, Issue 2, 1997, Pages 308-326

  Zimmermann, Anthony E ^b,c   Katona, Brian G ^a  

^a Astra Merck Inc   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c BAYSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FAMOTIDINE; FOLIC ACID; GASTRIN; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; IRON; LANSOPRAZOLE; OMEPRAZOLE; RANITIDINE; THYROTROPIN;

ACID SECRETION; ANALGESIA; BACTERIAL OVERGROWTH; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG METABOLISM; DUODENUM ULCER; ESOPHAGITIS; GASTRIN BLOOD LEVEL; GASTRIN CELL; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; REFLUX ESOPHAGITIS; REVIEW; STOMACH PARIETAL CELL; STOMACH SECRETION; STOMACH ULCER; ULCER; ULCER HEALING; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; DRUG INTERACTIONS; ENZYME INHIBITORS; GASTRIC ACID; H(+)-K(+)-EXCHANGING ATPASE; HELICOBACTER INFECTIONS; HUMANS; OMEPRAZOLE; PEPTIC ULCER; PROTON PUMPS;

EID: 0030893857     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (184)

1. Barradell LB, Faulds D, McTavish D. Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992;44:225-50.
2. Spencer CM, Faulds D. Lansoprazole: a reapprisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994;48:404-30.
3. Anonymous. Lansoprazole. Drugs of the Future 1989;14: 625-7.
4. Delhotal Landes B, Petite JP, Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995;28:458-70.
5. Berglindh T, Helander HF, Obrink KJ. Effects of secretagogues on oxygen consumption, aminopyrine accumulation and morphology in isolated gastric glands. Acta Physiol Scand 1976;97:401-14.
6. +-ATPase. Nature 1981;290:159-61.
7. Massoomi F, Savage J, Destache CJ. Omeprazole: a comprehensive review. Pharmacotherapy 1993;13:46-59.
8. Sachs G, Chang HH, Rabon E, et al. A nonelectrogenic H pump in plasma membranes of hog stomach. J Biol Chem 1976;251:7690-8.
9. Shull G, Lingrel JB. Molecular cloning of the rat stomach H+,K+-ATPase. J Biol Chem 1986;261:123-6.
10. Chow DC, Cathy MB, Fore JG. Gastric H+,K+-ATPase activity inhibited by reduction of disulfide bonds in beta subunit. Am J Physiol 1992;263:C39-46.
11. Gilbert A, Hersey SJ. Morphometric analysis of parietal cell membrane transformations in isolated gastric glands. J Membr Biol 1982;67:113-24.
12. Wolosin JM, Forte JG. Kinetic properties of the KC1 transport at the secreting apical membrane of the oxyntic cell. J Membr Biol 1983;71:195-207.
13. +)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther 1989;248:799-805.
14. Nagaya H, Satoh H, Maki Y. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cell. J Pharmacol Exp Ther 1990;252:1289-95.
15. Besancon M, Simon A, Sachs G. The critical cysteine in the gastric H,K ATPase for inhibition of acid secretion by proton pump inhibitors [abstr]. Gastroenterology 1995;108:A59.
16. 2-receptor antagonist famotidine in rats and dogs. Jpn J Pharmacol 1991;55:425-36.
17. Satoh H, Inatomi N, Nagaya H, et al. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J Pharmacol Exp Ther 1989;248:806-15.
18. Batayi A, Varai E, Holstein B, Mattsson H. The recovery rate of acid secretion in rats is similar following inhibition by lansoprazole, pantoprazole and omeprazole [abstr]. Gastroenterology 1993;104(suppl):A39.
19. Bruley Des Varannes S, Levy P, Lartigue S, et al. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994;8:309-14.
20. Berlin I, Molinier P, Duchier A, et al. Dose ranging study of lansoprazole, a new proton pump inhibitor, in patients with high gastric acid secretion. Eur J Clin Pharmacol 1992;43:117-19.
21. Muller P, Dammann HG, Leucht U, et al. Human gastric acid secretion following repeated doses of AG-1749. Aliment Pharmacol Ther 1989;3:193-8.
22. Vidon N, Dutreuil C, Scoule JC, Delchier JC. Does lansoprazole influence postprandial digestive function? Aliment Pharmacol Ther 1993;7:629-34.
23. Hogan DL, Koss MA, Feitelberg S, et al. Single and repetitive administration of lansoprazole: effects on gastric acid secretion, pharmacokinetics and serum gastrin in old vs. young subjects [abstr]. Gastroenterology 1991;100:A84.
24. Dammann HG, Von Zur Muhler A, Balks HJ, et al. The effects of lansoprazole, 30 or 60 mg/day, on intragastric pH and on endocrine function in healthy volunteers. Aliment Pharmacol Ther 1993;7:191-6.
25. +-ATPase inhibitor, on gastric pH and serum gastrin. Aliment Pharmacol Ther 1992;6:359-72.
26. Hongo M, Ohara S, Hirasawa Y, et al. Effect of lansoprazole on intragastric pH. Comparison between morning and evening doses. Dig Dis Sci 1992;37:882-990.
27. Verdu EF, Fraser R, Armstrong D, Blum AL. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers. Scand J Gastroenterol 1994;29:1065-9.
28. Bell NJV, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(suppl 1):59-67.
29. +, ATPase blocker (RU 749) on gastric emptying in man [abstr]. Gastroenterology 1989;96:A240.
30. Horowitz M, Hetzel DJ, Buckle PJ, et al. The effect of omeprazole on gastric emptying in patients with duodenal ulcer disease. Br J Clin Pharmacol 1984;18:791-4.
31. Rasmussen L, Oster-Jorgensen E, Qvist N, et al. Short report: a double-blind placebo controlled trial of omeprazole on characteristics of gastric emptying in healthy subjects. Aliment Pharmacol Ther 1991;5:85-9.
32. Bins M, Burgers PIC, Selbach SGM, et al. The relation between basal gastric pH and serum gastrin. Digestion 1982;23:271-3.
33. Ryberg B, Axelson J, Hakanson R, et al. Trophic effects of continuous infusion of (Leu15)-gastrin-17 in the rat. Gastroenterology 1990;98:33-8.
34. Ryberg B, Tielemans Y, Axelson J, et al. Gastrin stimulates the self-replication rate of enterochromaffinlike cells in the rat stomach. Gastroenterology 1990;99:935-42.
35. Hakanson R, Bottcher G, Ekblad E, et al. Histamine in endocrine cells in the stomach. A survey of several species using a panel of histamine antibodies. Histochemistry 1986;86:5-17.
36. Kubota H, Taguchi Y, Tohyama M, et al. Electron microscopic identification of histidine decarboxylase-containing endocrine cells of the rat gastric mucosa: an immunohistochemical analysis. Gastroenterology 1984;87: 496-502.
37. Bell NJV, Chiba N, Ringham GL, et al. Time to maximum effect of lansoprazole on gastric pH in male, normal volunteers [abstr]. Gastroenterology 1992;102:A40.
38. Bergman JF, Forestier S, Joubert M. Evolution of gastrinemia after treatment with lansoprazole in duodenal ulcer (DU) and reflux esophagitis (RE) [abstr]. Gastroenterology 1993;104:A42.
39. Seensalu R, Iwarzon M, Janczewska I, et al. Dose-response comparison of lansoprazole and omeprazole on 24-hour gastric acidity and plasma gastrin in healthy volunteers [abstr]. Gastroenterology 1995;108:A215.
40. Eissele R, Brunner G, Fischer B, et al. Evaluation of enterochromaffin-like (ECL)-cell hyperplasia during long-term treatment with the proton pump inhibitor lansoprazole [abstr]. Gastroenterology 1993;104:A74.
41. Berlin RG. Omeprazole. Gastric and gastric endocrine data from clinical studies. Dig Dis Sci 1991;36:129-36.
42. Pinson DM, Havu N, Sztern MI, et al. Drug-induced hypergastrinemia: absence of trophic effects on colonic carcinoma in rats. Gastroenterology 1995;108:1068-74.
43. Orbuch M, Lubensky IA, Weber HC, et al. Prolonged marked hypergastrinemia does not increase the rate of colonic neoplasia [abstr]. Gastroenterology 1994;106:A151.
44. Geboes K, Ectors N, Person J. Long-term lansoprazole treatment in man: effects on gastric mucosa histology [abstr]. Gastroenterology 1995;108:A99.
45. MacGilchrist AJ, Howden CW, Kenyon CJ, et al. The effects of omeprazole on endocrine function in man. Eur J Clin Pharmacol 1987;32:423-5.
46. Howden CW, Kenyon CJ, Beastal GH, Reid JL. Inhibition by omeprazole of adrenocortical response to ACTH: clinical studies and experiments on bovine adrenal cortex in vitro. Clin Sci 1986;70:99-101.
47. TAP Pharmaceutical Inc. Prevacid (lansoprazole) package circular. Deerfield, IL; 1995.
48. Gaetani M, Buratti P, Pasquali R, et al. Chronic oral administration with lansoprazole does not affect gonadotropin pulsatile pattern in healthy males [abstr]. Gastroenterology 1995;108:A84.
49. Herzlich B, Herbert V. Rapid collection of human intrinsic factor uncontaminated with cobalophilin (R binder). Am J Gastroenterol 1986;81:678-80.
50. 12) absorption. Am J Gastroenterol 1984;79:489-93.
51. 12 binding proteins. Gut 1990;31:59-63.
52. Marcuard SP, Albernaz L, Khzanic PG. Omeprazole therapy causes malabsorption of cyanocobalamin. Ann Intern Med 1994;120:211-15.
53. 12 during prolonged omeprazole therapy. J Clin Gastroenterol 1992;14:288-92.
54. 12 absorption. J Am Coll Nutr 1994;13:584-91.
55. Saltzman JR, Kowdley KV, Pedrosa MC, et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology 1994;106:615-23.
56. Fried M, Siegrist H, Froehlich F, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994;35:23-6.
57. Sharma BK, Santana IA, Wood EC, et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br Med J 1984;289:717-19.
58. Moules I, Garrett A, Brockelbank D, et al. Gastric acid inhibition by proton pump inhibitor lansoprazole is unaffected by food. Br J Clin Res 1993;4:153-61.
59. Chun AHC, Eason CJ, Shi HH, Cavanaugh JH. Lansoprazole: an alternative method of administration of a capsule dosage formulation. Clin Ther 1995;17:441-6.
60. Delhotal-Landes B, Flouvat B, Duchier J, et al. Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 1993;45:367-71.
61. Mitani M, Tsukamoto T, Yoshida S, Kobayashi T. Metabolic fate of AG-1749, a new proton pump inhibitor, in rats, mice, and dogs. Jpn Pharmacol Ther 1990;18:3413-35.
62. Flouvat B, Delhotal Landes B, Dellatolas F, et al. Pharmacocinetique du lansoprazole ou AG-1749 ou RU 49749 chez le sujet sain. Symposium LANZOR, Paris, April 12, 1991.
63. Coste T, Logeais C, Delhotal-Landes B, et al. Pharmacokinetics of lansoprazole after repeated administration in cirrhosis patients [abstr]. Gastroenterology 1993;104:A59.
64. Pichard L, Curi-Pedrosa R, Bonfils C, et al. Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 1995;47:410-18.
65. Curi-Pedrosa R, Pichard L, Bonfils C, et al. Major implication of cytochrome P450 3A4 in the oxidative metabolism of the antisecretory drugs omeprazole and lansoprazole in human liver microsomes and hepatocytes. Br J Clin Pharmacol 1993;36:156.
66. Sohn D-R, Kwon J-T, Kim H-K. Influence of S-mephenytoin phenotype on lansoprazole metabolism. Clin Pharmacol Ther 1996;59:137.
67. Siringo S, Bolondi L, Gramantieri L, et al. Pharmacokinetics of lansoprazole in cirrhotics with different degrees of liver function derangement [abstr]. Gastroenterology 1995;108:A221.
68. Tateno M, Nakamura N. Phase 1 study of lansoprazole (AG-1749) antiulcer agent. Capsule form. Rinsho Iyaku 1991;7:51-62.
69. Hussein Z, Grannemen GR, Mujherjee D, et al. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 1993;36:391-8.
70. Flouvat B, Delhotal-Landes B, Cournot A, et al. Single and multiple dose pharmacokinetics of lansoprazole in elderly patients. Br J Clin Pharmacol 1993;36:467-9.
71. Aaronson R, Dorsch E, Padgett C, et al. Lansoprazole heals duodenal ulcers. Presented at the American College of Gastroenterology, Boston, MA, October 14-16, 1991.
72. Londong W, Barth H, Dammann HG, et al. Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole. Aliment Pharmacol Ther 1991;5(3):245-54.
73. Hotz J, Kleinert R, Grymbowski T, Hennig U, Schwarz JA. Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. Aliment Pharmacol Ther 1992;6:87-95.
74. Takemoto T, Namiki M, Goto Y, et al. A study of clinical usefulness of lansoprazole (AG-1749) in treating duodenal ulcer: a comparison with famotidine by the multiclinic, double-blind, controlled technique. Rinsho Seijinbyo 1991;21(3):613-31.
75. Takemoto T, Namiki M, Goto Y, et al. Studies of clinical usefulness of lansoprazole (AG-1749) in the treatment of gastric and duodenal ulcers. A study of usefulness of AG-1749 at a dosage of 30 mg/day, using famotidine as the control drug. Clin Adult Dis 1991;21(5):975-93.
76. Hawkey CJ, Long RG, Bardhan KD, et al. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. Gut 1993;34:1458-62.
77. Lanza F, Goff J, Scowcroft C, et al. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Am J Gastroenterol 1994;89(8): 1191-1200.
78. Florent C. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer. Clin Ther 1993;15(suppl B):14-21.
79. Ekstrom P, Unge P, Ahlberg J, et al. Lansoprazole vs omeprazole in active duodenal ulcer - a healing study [abstr]. Scand J Gastroenterol 1992;190(suppl 27):40.
80. Petite JP, Slama JL, Licht H, et al. Lansoprazole and omeprazole in the treatment of duodenal ulcer: a multicentric double-blind comparative trial. Gastroenterol Clin Biol 1993;17:334-40.
81. Mignon M, Vallot T. Acute treatment of duodenal ulcer: experience with lansoprazole. Aliment Pharmacol Ther 1993;7(suppl 1):37-40.
82. Lanza F, Goff J, Silvers D, et al. Lansoprazole for one year prevents recurrence of duodenal ulcer [abstr]. Gastroenterology 1994;106:A122.
83. Brunner G, Arnold R, Hennig U, Fuchs W. An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 1993;7(suppl 1):51-5.
84. Kodama T, Fuse Y, Ohkawawa Y, et al. Clinical effects of lansoprazole (AG-1749) on patients with gastric and duodenal ulcer. Yakuri To Chiryo 1990;18:4891-4900.
85. Misawa T, Chijiiwa Y, Imazono Y, et al. Effects of lansoprazole, a gastric proton pump inhibitor, on endocrine function and healing in patients with peptic ulcer. Ther Res 1991;12:175-338.
86. Morise K, Oka Y, Suzuki T, et al. Clinical evaluation of lansoprazole (AG-1749) in patients with gastric or duodenal ulcer. Yakuri To Chiryo 1991;19:327-38.
87. Ogoshi K, Kato T, Saito S, et al. Clinical study of AG-1749 (lansoprazole): effects on serum gastrin levels and gastric mucosal ECL cell density. Yakuri To Chiryo 1991;19:933-46.
88. Makiyama K, Umene Y, Murata I, Izuno M, Hara K. Clinical study on therapeutic effect of an antiulcer agent, lansoprazole, on gastric ulcer: with reference to serum gastrin concentration. Yakuri To Chiryo 1991;19:307-25.
89. Avner DL, Movva R, Nelson KJ, et al. Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcers. Am J Gastroenterol 1995;90(8):1289-94.
90. Freston JW. Future prospects for proton pump inhibitors. Aliment Pharmacol Ther 1993;7(suppl 1):68-75.
91. Londong W, Hotz J, Kleinert R, et al. Lansoprazole in gastric ulcer: a dose finding and comparative multicentre trial [abstr]. Hellenic J Gastroenterol 1992;5:A797.
92. Wormsley KG, Bardhan KD, Morgan AG, et al. Lansoprazole (LAN) is more effective than ranitidine (RAN) in the healing of gastric ulcer (GU). Gut 1992;33(suppl 1):T190.
93. Takemoto T, Namiki M, Goto Y, Matsuo Y, Miwa T. A study of clinical usefulness of lansoprazole (AG-1749) in treating gastric ulcers: a comparison with famotidine by multiclinic, double-blind technique. Rinsho Seijinbyo 1991;21(2):327-45.
94. Bardhan KD, Ahlberg J, Hislop WS, et al. Rapid healing of gastric ulcers with lansoprazole. Aliment Pharmacol Ther 1994;8(2):215-20.
95. Michel P, Lemaire M, Colin R, et al. Short report: treatment of gastric ulcer with lansoprazole or ranitidine: a multicentre clinical trial. Aliment Pharmacol Ther 1994;8:119-22.
96. Sorensen HT, Rasmussen HH, Ballev I, et al. Effect of omeprazole and sucralfate on prepyloric gastric ulcers. A double blind comparative and one year follow up. Gut 1994;35(6):837-40.
97. Kuwayama H, Matsuo Y, Eastwood GL. Effects of sucralfate lansoprazole, and cimetidine on the delayed healing by hydrocortisone sodium phosphate of chronic gastric ulcers in the rat. Am J Med 1991;91(2a):15S-19.
98. Florent C, Audigier JC, Boyer J, et al. Efficacy and safety of lansoprazole in the treatment of gastric ulcer: a multicentre study. Eur J Gastroenterol Hepatol 1994;6:1135-9.
99. Hoshino E, Shimizu Y, Miyashita H, Sano J. Lansoprazole: usefulness of a new proton pump inhibitor as maintenance therapy for gastric ulcer [abstr]. Gastroenterology 1994;106:A95.
100. 2-receptor antagonist-refractory ulcer: its pathophysiology and treatment. J Clin Gastroenterol 1991;13(suppl 1):129-33.
101. 2-receptor antagonists. Nippon Rinsho 1992;50(1):104-10.
102. Brunner G, Creutzfeldt W, Harke U, Lamberts S. Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment. Digestion 1988;38:80-90.
103. Metz DC, Pisegna JR, Fishbeyn VA, et al. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg 1993;17:468-80.
104. Hirschowitz BJ, Mohnen J, Shaw S. Zollinger-Ellison syndrome treated with lansoprazole [abstr]. Gastroenterology 1993;104:A100.
105. Mignon M, Hochlaf S, Forestier S, Ruszniewski P, Vatier J, Joubert-Collin M. Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome [abstr]. Gastroenterol Clin Biol 1994;18(1):13-16.
106. Ramdani A, Paul G, Ruszniewski P, et al. Comparative efficiency of lansoprazole and omeprazole on 24-hour intragastric pH measurement in 9 cases of Zollinger-Ellison syndrome [abstr] Gastroenterology 1992;102:A151.
107. Jensen RT, Metz DC, Koviack PD, Feigenbaum KM. Prospective study of the long-term efficacy and safety of lansoprazole in patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1993;7(suppl 1):41-50.
108. Mignon M, Pospai D, Forestier S, Vallot T. Treatment of patients with Zollinger-Ellison syndrome. Clin Ther 1993;15(suppl B):22-31.
109. Metz DC, Piseqna JR, Fishbeyn VA, et al. Current maintenance doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992;103: 1498-1508.
110. Dorsch E, Jones J, Padgett C, et al. Lansoprazole heals moderate to severe reflux esophagitis [abstr]. Am J Gastroenterol 1991;86:1294.
111. Bardhan KD, Hawkey CJ, Long R, et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. Aliment Pharmacol Ther 1995;9:145-51.
112. Robinson M, Kogut O, Jennings D, et al. Lansoprazole heals erosive reflux esophagitis better than ranitidine [abstr]. Gastroenterology 1992;102:A153.
113. Benhaim MC, Evreux M, Salducci J, Petite JP, Lemaire M. Lansoprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial [abstr]. Gastroenterology 1990;98:A20.
114. +-ATPase inhibitor: a controlled, double-blind study. Am J Gastroenterol 1993;88(8):1212-17.
115. Berstad A, Hatlebakk JG. Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies. Aliment Pharmacol Ther 1993;7(suppl 1):34-6.
116. Corallo J, Vicari F, Forestier S, et al. Lansoprazole in acute treatment of reflux esophagitis [abstr]. Gastroenterology 1993;104;A58.
117. Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Scand J Gastroenterol 1993;28:224-8.
118. Castell DO, Richter JE, Robinson M, Sontag S. Large trial compares lansoprazole to omeprazole [abstr]. Gastroenterology 1995;108:A67.
119. Rampal P, Courrier A, Lemerez M, et al. Efficacy and safety of lansoprazole 30 mg versus omeprazole for 21 days treatment of acute esophagitis [abstr]. Gastroenterology 1995;108;A200.
120. Umeda N, Miki K, Hoshino E. Lansoprazole vs. famotidine in symptomatic reflux esophagitis: a multicenter randomized crossover study. J Clin Gastroenterol 1995;20(suppl 1):S17-23.
121. Mee AS, Rowley JL, and the Lansoprazole Study Group. Lansoprazole provides greater symptom relief than omeprazole in reflux esophagitis [abstr]. Gastroenterology 1995;108:A164.
122. Mathias S, Castell D, Elkin E, Liberman R. The health-related quality-of-life benefits of treatment with lansoprazole versus omeprazole for erosive reflux esophagitis [abstr]. Gastroenterology 1995;108:A160.
123. 2-receptor antagonist therapy [abstr]. Gastroenterology 1992;102:A167.
124. Bardham KD. Is there any acid peptic disease that is refractory to proton pump inhibitors? Aliment Pharmacol Ther 1993;7(suppl 1):13-24.
125. 2 resistant erosive reflux esophagitis [abstr]. Gastroenterology 1990;98:A113.
126. 2-receptor antagonist therapy: lansoprazole, a new proton pump inhibitor. Dig Dis Sci 1995;40(3):590-7.
127. Dobrilla G, DiFede F. Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview. Clin Ther 1993; 15(suppl B):3-12.
128. Hatlebakk JG, Berstad A. Lansoprazole 15 and 30 mg/day in long-term treatment of erosive reflux esophagitis [abstr]. Gastroenterology 1995;108:A111.
129. Poynard T, Staub JL, Lemerez M, et al. Efficacy and safety of lansoprazole 15 mg or 30 mg as one year maintenance treatment for erosive reflux esophagitis [abstr]. Gastroenterology 1995;108:A195.
130. Sontag SJ, Richter J, Campbell D, et al. Lansoprazole (LAN) for one year prevents recurrence of resistant erosive reflux esophagitis (ERE) [abstr 73]. Am J Gastroenterol 1993;88: 1499.
131. Robinson M, Lanza F, and the Lansoprazole Study Group Lansoprazole for one year prevents recurrence of erosive reflux esophagitis [abstr]. Gastroenterology 1994;106:A166.
132. 2 blockers [abstr]. Gastroenterology 1993;104:A79.
133. Swarbrick ET, Gough AL, Christian J, et al. Prevention of recurrence of oesophageal stricture: a comparative study of lansoprazole and high-dose ranitidine [abstr]. Gastroenterology 1994;106:A189.
134. Peters FTM, Kleibeuker JH. Barrett's oesophagus and carcinoma. Scand J Gastroenterol 1993;28(suppl 200):59-64.
135. Sontag SJ, Schnell TG, Kurucar C, Rose P, Jennings D. Lansoprazole (LAN) heals erosive reflux esophagitis (ERE) in patients (PTS) with Barrett's esophagus (BE) [abstr 74]. Am J Gastroenterol 1993;88:1499.
136. Sampliner RE, Romero R, LaFleur L. Effects of up to 3 years of high dose lansoprazole on Barrett's esophagus [abstr]. Gastroenterology 1994;106:A172.
137. Misiewicz JJ. Helicobacter pylori: past, present and future. Scand J Gastroenterol 1992;27:25-9.
138. Lamouliatte H. Effect of lansoprazole on Heticobacter pylori. Clin Ther 1993;15:32-6.
139. Harris AW, Gummett PA, Logan RP, et al. Eradication of Helicobacter pylori with lansoprazole and clarithromycin. Aliment Pharmacol Ther 1995;9:201-4.
140. Megraud F, Boyanova L, Lamouliatte H. Activity of lansoprazole against Helicobacter pylori. Lancet 1991;337:1486.
141. Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991;35(3):490-6.
142. Cohen JC. Evolving therapies for peptic ulcer disease: Helicobacter pylori treatment. Gastroenterologist 1995;3(4):289-300.
143. Verdu EF, Fraser R, Armstrong D, Blum AL. Lansoprazole and omeprazole, at therapeutic doses, produce equivalent rises in gastric pH in Helicobacter pylori (HP) positive patients [abstr]. Gastroenterology 1994;106:A205.
144. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
145. Louw JA, Lucke W, Jasklewicz K, et al. Helicobacter pylori suppression by the proton pump inhibitors (PPIs): a class effect? [abstr]. S Afr Med J 1993;83:784.
146. Lamouliatte H. Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole in clinical studies. J Clin Gastroenterol 1995;20(suppl 1):S28-31.
147. Yamamoto I, Yoshihiko F, Okui M, et al. Proton pump inhibitors for Helicobacter pylori eradication in patients with peptic ulcer. J Clin Gastroenterol 1995;20(suppl 1):S38-42.
148. Bayerdorffer E, Schulz H, Simon T, et al. Double-blind trial of lansoprazole plus amoxicillin versus lansoprazole plus clarithromycin for cure of Helicobacter pylori infection in duodenal ulcer patients [abstr]. Gastroenterology 1995;108: A57.
149. Matsukura N, Onda M, Yamashita K. Helicobacter pylori in peptic ulcer and gastric cancer (Japanese). Gan To Kagaku Ryoho 1995;22(2):169-78.
150. Kohli Y, Kato T, Azuma T, et al. Lansoprazole treatment of Helicobacter pylori-positive peptic ulcer. J Clin Gastroenterol 1995;20(suppl 1):S48-51.
151. Phull P, Price AB, Halliday D, et al. Lansoprazole plus clarithromycin: evaluation of a new dual therapy for H. pylori eradication [abstr]. Gastroenterology 1995;108:A191.
152. Takimoto T, Kimura K, Taniguchi Y, et al. Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1995;7(suppl 1):S63-6.
153. De Korwin JD, Joubert M, Bazin N, et al. Lansoprazole versus lansoprazole plus antibiotics in the treatment of Helicobacter pylori gastric infection [abstr]. Gastroenterology 1993;104:A67.
154. Saita H, Murakami M, Dekigai H, et al. Two weeks combination therapy with lansoprazole and amoxicillin for eradication of H. pylori [abstr]. Gastroenterology 1994;106:A171.
155. Pallone F, Luzza F. Lansoprazole and Helicobacter pylori infection. Clin Ther 1993;15(suppl B):49-57.
156. Asaka J, Ohtaki T, Kato M, et al. Causal role of Helicobacter pylori in peptic ulcer relapse. J Gastroenterol 1994;29(suppl 7):134-8.
157. Kadayifci A, Simsek H, Tatar G, Arslan M, Oksuzoglu G. Low eradication rates of Helicobacter pylori with omeprazole plus amoxicillin therapy [abstr]. Gastroenterology 1995;108:A127.
158. Kalach N, Benhamou PH, Raymond J, et al. A controlled study of the efficacy of lansoprazole in combination with two different dual antibiotic associations during Helicobacter pylori (H. pylori) gastric infection in children [abstr]. Gastroenterology 1995;108:A127.
159. Cayla R, Zerbib F, Megraud F, Lamouliatte H. Clarithromycin resistance of Helicobacter pylori strains before and after treatment: a key factor of treatment failures [abstr]. Gastroenterology 1995;108:A68.
160. Cayla R, de Mascarel A, Zerbib F, et al. High dose of lansoprazole plus amoxicillin versus high dose of lansoprazole plus amoxicillin and clarithromycin for Helicobacter pylori (H. pylori) infection [abstr]. Gastroenterology 1995;108:A68.
161. Soll AH. Medical treatment of peptic ulcer disease. JAMA 1996;275(8):622-30.
162. Ozmen MM. Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication? Am J Gastroenterol 1995;90(9):1542-3.
163. Burette A, Glupczynski Y, Deprez C, et al. Lansoprazole plus roxythromycin and metronidazole for eradication of H. pylori: results of a single-blind pilot study [abstr]. Gastroenterology 1993;104:A49.
164. Axon ATR. The potential value of lansoprazole in Helicobacter pylori eradication. J Clin Gastroenterol 1995;20(suppl 1):S43-7.
165. Cayla R, Zerbib F, de Mascarel A, et al. High dose of lansoprazole in combination with amoxicillin and clarithromycin twice daily for H. pylori eradication: results of a pilot study [abstr]. Am J Gastroenterol 1994;89:A327.
166. Bazzoll F, Gullini S, Zagari RM, et al. Effect of omeprazole and clarithromycin plus tinidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer [abstr]. Gastroenterology 1995;108:A57.
167. Kimura K, Kenichi I, Saifuku K, et al. A 1-h topical therapy for the treatment of Helicobacter pylori infection. Am J Gastroenterol 1995;90(1):60-3.
168. Cole AT, Maclntyre AS, Hawkey GM, et al. Lansoprazole and tranexamic acid alone and in combination for upper gastrointestinal bleeding [abstr]. Gastroenterology 1995;108:A74.
169. Colin-Jones DG. Safety of lansoprazole. Aliment Pharmacol Ther 1993;7(suppl 1):56-60.
170. Colin-Jones D. Treatment of acid-peptic disease: focus on proton pump inhibitors. Aliment Pharmacol Ther 1993;7(suppl 1):66.
171. Fuchs W, Sennewald R, Klotz U. Lansoprazole does not affect the bioavailability of oral contraceptives. Br J Clin Pharmacol 1994;38:376-80.
172. Galbraith RA, Michnovicz JJ. Omeprazole fails to alter the cytochrome P450-dependent 2-hydroxylation of estradiol in male volunteers. Pharmacology 1993;47:8-12.
173. Lefebve RA, Flouvant B, Karolac-Tamisier S, et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 1992;52:458-63.
174. Andersson T, Regardh CG, Lou YC, et al. Polymorphic hydroxylation of S-mephenytoin and omeprazole in Caucasian and Oriental subjects. Pharmacogenetics 1992;2:25-31.
175. Andersson T, Miners JO, Veronese ME. Identification of liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993;36:521-30.
176. Branneman G, Winters EP, Locke CS, et al. Lack of effect of concomitant lansoprazole on steady state theophylline pharmacokinetics [abstr]. Gastroenterology 1991;100:A75.
177. Roux A, Naline R, Molinier P, et al. Effect of lansoprazole and omeprazole on the metabolism of theophylline and antipyrine in man [abstr]. Eur J Drug Metab Pharmacokinet 1993;18:125.
178. Delhotal-Landes B, Cournot A, Vermerie N, et al. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet 1991;Spec #3:315-20.
179. Gerloff J, Barth H, Mignot A, et al. Does the proton pump inhibitor lansoprazole interact with antacids [abstr]. Naunyn Schmiedebergs Arch Pharmacol 1993;347:R31.
180. Cavanaugh JL, Locke C, Shi H, et al. Assessment of the effect of sucralfate on the bioavailability of lansoprazole and omeprazole [abstr]. Am J Gastroenterol 1995;90:1577.
181. Cavanaugh JL, Schneck DW, Mukherji D, Karol MD. Lack of effect of concomitant lansoprazole on single-dose propranolol pharmacokinetics and pharmacodynamics [abstr]. Gastroenterology 1994;106:A4.
182. Cavanaugh JL, Winters EP, Cohen A, Locke CS. Lack of effect of lansoprazole on steady state warfarin metabolism [abstr]. Gastroenterology 1991;100:A40.
183. Cavanaugh JL, Locke C, Karol N. Lack of interaction of lansoprazole or omeprazole with prednisone [abstr]. Am J Gastroenterol 1993;88:1589.
184. Anonymous. 1996 red book. Montvale, NJ: Medical Economics, 1996.